[go: up one dir, main page]

ES2723827T3 - Terapia de combinación de fármacos para el tratamiento de tumores sólidos - Google Patents

Terapia de combinación de fármacos para el tratamiento de tumores sólidos Download PDF

Info

Publication number
ES2723827T3
ES2723827T3 ES12848554T ES12848554T ES2723827T3 ES 2723827 T3 ES2723827 T3 ES 2723827T3 ES 12848554 T ES12848554 T ES 12848554T ES 12848554 T ES12848554 T ES 12848554T ES 2723827 T3 ES2723827 T3 ES 2723827T3
Authority
ES
Spain
Prior art keywords
treatment
solid tumors
drug therapy
combination drug
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12848554T
Other languages
English (en)
Inventor
Herbert I Hurwitz
Gordana Vlahovic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Application granted granted Critical
Publication of ES2723827T3 publication Critical patent/ES2723827T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Un inhibidor de IGF1R, o una composición farmacéutica del mismo, en combinación con un inhibidor de mTOR, o una composición farmacéutica del mismo, para su uso en un método de tratamiento de cáncer de pulmón no microcítico (NSCLC) en un sujeto, en donde el inhibidor de IGF1R comprende un anticuerpo, en donde el anticuerpo es ganitumab, y en donde el inhibidor de mTOR comprende everolimus.
ES12848554T 2011-11-11 2012-11-09 Terapia de combinación de fármacos para el tratamiento de tumores sólidos Active ES2723827T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161558732P 2011-11-11 2011-11-11
PCT/US2012/064376 WO2013071056A2 (en) 2011-11-11 2012-11-09 Combination drug therapy for the treatment of solid tumors

Publications (1)

Publication Number Publication Date
ES2723827T3 true ES2723827T3 (es) 2019-09-02

Family

ID=48290768

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12848554T Active ES2723827T3 (es) 2011-11-11 2012-11-09 Terapia de combinación de fármacos para el tratamiento de tumores sólidos

Country Status (7)

Country Link
US (2) US9700619B2 (es)
EP (1) EP2776042B1 (es)
JP (1) JP6268097B2 (es)
AU (1) AU2012335541B2 (es)
CA (1) CA2852127C (es)
ES (1) ES2723827T3 (es)
WO (1) WO2013071056A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2856803A1 (en) * 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
EP3074019A1 (en) * 2013-11-27 2016-10-05 Oncoethix GmbH Method of treating non-small-cell lung cancer using pharmaceutical formulation containing thienotriazolodiazepine compounds
EP3154549A1 (en) * 2014-06-13 2017-04-19 Oncoethix GmbH Method of treating non-small cell lung cancer and/or small cell lung cancer using thienotriazolodiazepine compounds
HK1243940A1 (zh) 2014-11-06 2018-07-27 Scholar Rock, Inc. 抗原肌肉生长抑制素/潜在肌肉生长抑制素的抗体及其用途
JP2018527903A (ja) * 2015-07-22 2018-09-27 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． Ｇｄｆ１１結合タンパク質およびその使用
SMT202500263T1 (it) 2015-09-15 2025-09-12 Scholar Rock Inc Anticorpi anti-pro-miostatina/miostatina latente e loro usi
KR20180094110A (ko) 2016-01-08 2018-08-22 스칼러 락, 인크. 항-프로/잠재성 미오스타틴 항체 및 그의 사용 방법
KR102271635B1 (ko) 2016-06-13 2021-07-06 스칼러 락, 인크. 미오스타틴 억제제의 용도 및 조합 요법
DK3565592T5 (da) 2017-01-06 2024-09-02 Scholar Rock Inc Behandling af stofskiftesygdomme ved inhibering af myostatinaktivering
US20210332141A1 (en) * 2017-08-30 2021-10-28 Amgen Inc. Insulin-like growth factor-1 receptor (igf-1r) binding proteins and methods of use
TW202430247A (zh) 2022-12-22 2024-08-01 美商供石公司 肌肉生長抑制素活化之選擇性及強效抑制劑
US20250062020A1 (en) * 2023-08-14 2025-02-20 Tempus Ai, Inc. Systems and methods of radiomics based cancer stratification

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2714383B1 (fr) 1993-12-29 1996-02-09 Centre Nat Rech Scient Contrôle de l'expression de gènes.
DE69834828T2 (de) 1997-11-27 2007-01-04 Commonwealth Scientific And Industrial Research Organisation Verfahren zur konstruktion von agonisten und antagonisten des igf-rezeptors (1-462)
HK1040720A1 (zh) 1998-05-15 2002-06-21 伊姆克罗尼系统公司 用辐射和生长因子受体酪氨酸激酶抑制剂治疗人肿瘤
US6875741B2 (en) 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
US7173005B2 (en) 1998-09-02 2007-02-06 Antyra Inc. Insulin and IGF-1 receptor agonists and antagonists
US20030236190A1 (en) 1998-09-02 2003-12-25 Renuka Pillutla Isulin and IGF-1 receptor agonists and antagonists
EP1006184A1 (en) 1998-12-03 2000-06-07 F. Hoffmann-La Roche Ag IGF-1 receptor interacting proteins (IIPs) genes coding therefor and uses thereof
US6608108B2 (en) 1999-10-15 2003-08-19 Johns Hopkins University Method for treatment of tumors using nordihydroguaiaretic acid derivatives
UY27087A1 (es) 2001-01-05 2002-06-20 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina
EP1401476A4 (en) 2001-03-14 2006-03-08 Genentech Inc IGF ANTAGONIST PEPTIDES
SE0104140D0 (sv) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
MXPA04006980A (es) 2002-01-18 2004-11-10 Pf Medicament Anticuerpos novedosos anti-receptor del factor de crecimiento i tipo insulina, y usos de los mismos.
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
EP1432724A4 (en) 2002-02-20 2006-02-01 Sirna Therapeutics Inc INTERFERENCE MEDIATION INHIBITION OF GENE RNA FROM MAP KINASE
NZ571508A (en) 2002-05-24 2010-05-28 Schering Corp Neutralizing human anti-IGFR antibody
US8034904B2 (en) 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
JP2007528201A (ja) 2003-03-14 2007-10-11 ファルマシア・コーポレーション 癌治療のためのｉｇｆ−ｉ受容体に対する抗体
JP4473257B2 (ja) 2003-04-02 2010-06-02 エフ．ホフマン−ラ ロシュ アーゲー インスリン様成長因子ｉ受容体に対する抗体及びその使用
EP2365001A3 (en) 2003-05-01 2012-03-28 Imclone LLC Fully human antibodies directed against the human insulin-like growth factor-1 receptor
US7579157B2 (en) 2003-07-10 2009-08-25 Hoffmann-La Roche Inc. Antibody selection method against IGF-IR
BRPI0415395A (pt) 2003-10-15 2006-12-12 Osi Pharm Inc composto, métodos para inibir a atividade da proteìna quinase e para tratar um paciente que tenha uma condição que seja mediada pela atividade da proteìna quinase, e, composição
AR046639A1 (es) 2003-11-21 2005-12-14 Schering Corp Combinaciones terapeuticas de anticuerpo anti- igfr1
WO2005058967A2 (en) 2003-12-16 2005-06-30 Pierre Fabre Medicament Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof
ATE514434T1 (de) 2004-02-25 2011-07-15 Dana Farber Cancer Inst Inc Hemmer des insulinartigen wachstumsfaktor- rezeptors-1 zur hemmung von tumorzellwachstum
CA2555745C (en) 2004-03-12 2011-05-31 Analytecon S.A. Tetrahydroisoquinoline-and tetrahydrobenzazepine derivatives as igf-1r inhibitors
AR048518A1 (es) 2004-04-02 2006-05-03 Osi Pharm Inc Inhibidores heterobiciclicos de proteina quinasas sustituidos con anillos 6,6 -biciclicos
EP1759020A4 (en) 2004-06-21 2008-04-16 Exelixis Inc ACACS AS MODIFICATORS OF THE IGF PATH AND METHOD OF USE
AR053090A1 (es) 2004-07-20 2007-04-25 Osi Pharm Inc Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
FR2873699B1 (fr) 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
BRPI0514094A (pt) 2004-08-02 2008-05-27 Osi Pharm Inc composto, composição, e, método de tratamento de distúrbio hiperproliferativo
GB0426154D0 (en) 2004-11-29 2004-12-29 European Molecular Biology Lab Embl IGF-1 novel peptides
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
EP1841760B1 (en) 2004-12-30 2011-08-10 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
WO2006097800A2 (en) 2005-02-10 2006-09-21 UNIVERSITÄT KARLSRUHE (TH) FORSCHUNGSUNIVERSITÄT-GEGRüNDET 1825 Method and device for determining material properties
EP1885855A4 (en) 2005-05-05 2009-03-04 Valorisation Hsj Soc En Comman CYTOKIN RECEPTOR MODULATORS AND USES THEREOF
CA2680945C (en) 2005-06-17 2014-03-18 Imclone Systems Incorporated Anti-pdgfralpha antibodies
WO2007000328A1 (en) 2005-06-27 2007-01-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Antibodies that bind to an epitope on insulin-like growth factor 1 receptor and uses thereof
FR2888850B1 (fr) 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
CA2621820A1 (en) 2005-09-09 2007-03-15 Jan Gunzinger Isoquinolines derivatives as igf-1r inhibitors
EA200800785A1 (ru) 2005-09-09 2008-08-29 Аналитикон С.А. 4-арил-1,4-дигидро-3(2н)-изохинолиноны и 4-арил-1,2,3,4-тетрагидроизохинолины в качестве ингибиторов igf-1r и в качестве фармакологического средства в тест-системах, фармацевтическая композиция и изделие на их основе и способ лечения заболеваний, опосредованных igf-1 рецептором
CN101304996A (zh) 2005-09-16 2008-11-12 阿斯利康(瑞典)有限公司 抑制igf-1r酪氨酸激酶活性的嘧啶衍生物
WO2007095113A2 (en) 2006-02-10 2007-08-23 Massachusetts Institute Of Technology Cpg15 and cpg15-2 compounds and inhibitors as insulin receptor and insulin-like growth factor receptor agonists and antagonists
EP1999131B1 (en) 2006-03-03 2013-10-23 Nerviano Medical Sciences S.r.l. Bicyclo-pyrazoles active as kinase inhibitors
WO2007099166A1 (en) 2006-03-03 2007-09-07 Nerviano Medical Sciences S.R.L. Pyrazolo-pyridine derivatives active as kinase inhibitors
JP2009532027A (ja) 2006-03-28 2009-09-10 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗ｉｇｆ−１ｒ抗体およびその使用
EP2129397B1 (en) 2007-03-02 2018-10-31 Amgen, Inc. Methods and compositions for treating tumor diseases
US20090263397A1 (en) * 2007-07-06 2009-10-22 Buck Elizabeth A Combination anti-cancer therapy
JP2010532756A (ja) 2007-07-06 2010-10-14 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド ｍＴＯＲＣ１及びｍＴＯＲＣ２の両方の阻害剤を含む組み合わせ抗癌療法
WO2010120599A2 (en) * 2009-04-16 2010-10-21 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
WO2010146059A2 (en) * 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy

Also Published As

Publication number Publication date
WO2013071056A3 (en) 2013-07-11
AU2012335541A1 (en) 2014-04-17
US20150044223A1 (en) 2015-02-12
JP2014533277A (ja) 2014-12-11
EP2776042B1 (en) 2019-03-20
US9931402B2 (en) 2018-04-03
EP2776042A2 (en) 2014-09-17
CA2852127A1 (en) 2013-05-16
AU2012335541B2 (en) 2017-07-06
CA2852127C (en) 2020-10-27
US9700619B2 (en) 2017-07-11
JP6268097B2 (ja) 2018-01-24
EP2776042A4 (en) 2015-10-07
WO2013071056A2 (en) 2013-05-16
US20170239352A1 (en) 2017-08-24

Similar Documents

Publication Publication Date Title
ES2723827T3 (es) Terapia de combinación de fármacos para el tratamiento de tumores sólidos
CY1124298T1 (el) Φενφλουραμινη για χρηση στην θεραπευτικη αντιμετωπιση του συνδρομου dravet
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
EA201490194A1 (ru) Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака
EA201300810A1 (ru) Противораковая терапия с использованием двойных ингибиторов киназ аврора/мек
CA3019531A1 (en) Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
EA201491584A1 (ru) Способы лечения немелкоклеточного рака легких c применением комбинированного лечения с ингибитором киназы tor
CO7350624A2 (es) Inhibidores de la tirosina-quinasa de bruton
AU2013299841A8 (en) Pharmaceutical combinations comprising a B-Raf inhibitor, an EGFR inhibitor and optionally a PI3K-alpha inhibitor
MX393974B (es) Terapia de combinacion para tratamiento de cancer.
WO2011112953A3 (en) Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
EA201100335A8 (ru) Производные пурина для применения при лечении связанных с fab заболеваний
WO2015054619A3 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
MX2015011466A (es) Uso de linagliptina en terapia antidiabetica cardio-y renoprotectora.
MX379286B (es) INHIBIDORES DE PCSK9 PARA USARSE EN EL TRATAMIENTO DE PACIENTES CON HIPERCOLESTEROLEMIA FAMILIAR HETEROCIGOTA (HFHe).
BR112014024017A8 (pt) Métodos de tratamento de um tipo de câncer, de tratamento do carcinoma, para selecionar uma terapia e para quantificação e inibidor de her3
BR112014011925A2 (pt) mutações no receptor notch humano e seu uso
BR112017005598A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
BR112012022243A8 (pt) Uso de um inibidor de autofagia baseado em tioxantona e de um composto indutor de autofagia para terapia de câncer, composição farmacêutica e kit farmacêutico
EA201691385A1 (ru) Комбинированная терапия рака
WO2013104050A3 (en) Methods of treating triple negative breast cancer and basal-like breast cancer using inhibitors against kidney associated 1 (kaag1) inhibitor
CL2012002858A1 (es) Combinación farmacéutica que comprende 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencilamidazol-2-il-quinolin-2-ona y al menos un inhibidor de mtor; método de tratamiento; y uso para el tratamiento y la prevención de una enfermedad proliferativa tal como cáncer de mama, tumores neuroendocrinos y linfonas, entre otras.
CL2012003201A1 (es) Metodo para tratar una cdi en un mamifero que esta siendo sometido simultaneamente a una terapia con antibioticos para combatir una infeccion diferente, que comprende el uso de fidaxomicina.
EA201391438A1 (ru) Производные сулиндака, применение и получение указанных производных